Dr. Han-Chung Wu is currently a Distinguished Research Fellow of the Institute of Cellular and Organismic Biology, Academia Sinica, Taiwan. He is also a Professor at the College of Medicine of the National Taiwan University. His research primarily focuses on two fields, cancer research and infectious diseases, and includes components of both basic research and applied science. Dr. Wu's research interest focuses on the identification of novel tumor antigens and study their functional roles in tumorigenesis, development of targeting drug delivery systems for cancer therapy and molecular imaging. He has developed phage display technologies that have been used for the generation of fully human monoclonal antibodies and the identification of peptides for a variety of target molecules. To date, Dr. Wu has published over 125 original articles in world-renowned journals, and 117 Patents (including 80 granted patents and 37 filed patents). He has successfully licensed out 20 technologies from 68 patents to biotech companies. Seven of the licensed technologies serve as the basis for products that are currently in clinical trials or already on the market. Seven of the licensed technologies are currently in preclinical studies for the development of therapeutics. Hence, his research results not only have significant value in basic research, but also practical applications with tangible contributions to the development of the biotech industry and drug development. Dr. Wu was elected as a Fellow of the National Academy of Inventors (NAI) of the United States in 2020. This is among the highest achievable honors for an academic inventor. Recently, Dr. Wu’s group has generated many monoclonal antibodies against the spike and NP proteins of SARS-CoV-2. Some of these monoclonal antibodies have been applied in COVID-19 antigen and IgG/IgM rapid tests with high sensitivity and specificity, two of which were approved by the Taiwan FDA. In addition, the group has also successfully developed therapeutic antibodies for COVID-19. These therapeutic antibodies target distinct epitopes of SARS-CoV-2 spike protein and can be used in combination to increase therapeutic efficacy and decrease the potential for virus escape mutants. These novel antibodies exhibit high SARS-CoV-2 neutralizing potency and great potential for use against common mutation variants in the prevention and treatment of COVID-19.